Home

search

Subjectguide
Journals
Books / Serials / Multimedia
Services
Services

Login for Subscribers
Logout

Sitemap
Help
Contacts


Logo






Vol. 69, No. 5, 2005   

Free Abstract     Article (Fulltext)     Article (PDF 124 KB)     

Clinical Study

Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial
J. Souglakos, A. Pallis, S. Kakolyris, D. Mavroudis, N. Androulakis, C. Kouroussis, S. Agelaki, N. Xenidis, G. Milaki, V. Georgoulias

Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, Heraklion, Crete, Greece

Address of Corresponding Author

Oncology 2005;69:384-390 (DOI: 10.1159/000089992)


 goto top of page Key Words

  • Irinotecan
  • Metastatic colorectal cancer
  • Elderly patients

 goto top of page Abstract

Purpose: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC). Methods: Thirty consecutive, previously untreated patients with metastatic colorectal cancer, aged (median 76 years; range 70-84) were enrolled. The performance status (WHO) was 0 in 8, 1 in 16 and 2 in 6 patients; 19 (63%) patients had prior surgery and 8 (27%) adjuvant chemotherapy. CPT-11 (180 mg/m2 as a 90 min i.v. infusion) was administered on day 1, LV (200 mg/m2 as a 2-hour i.v. infusion), 5-FU (400 mg/m2/d i.v. bolus followed by 600 mg/m2/d as a 22-hour i.v. continuous infusion) were given on days 1 and 2 every 2 weeks. Results: Complete response was achieved in one (3.3%) patient and partial response in 10 (33.3%) (overall response rate: 36.6%; 95% C.I.: 26.6-48.4%); 11 (36.6%) patients had stable disease and, 8 (26.6%) disease progression. The median duration of response was 7.5 months and the median time to disease progression 7.0 months. After a median follow-up period of 17 months, the median overall survival was 14.5 months. Main toxicities were: grade 3-4 neutropenia (n = 6; 20%), grade 3 thrombocytopenia (n = 1; 3.3%), grade 2 anemia (n = 9; 30%), grade 3-4 diarrhea (n = 5; 17%) and grade 3 asthenia (n = 3; 10%). There was one treatment-related death due to neutropenic sepsis. Conclusions: The FOLFIRI combination is an active regimen with manageable toxicity as front-line treatment in patients above 70 years of age.

Copyright © 2005 S. Karger AG, Basel


 goto top of page Author Contacts

Dr. Vassilis Georgoulias, MD, PhD
Department of Medical Oncology
University General Hospital of Heraklion, PO Box 1352
GR-71110 Heraklion, Crete (Greece)
Tel. +30 2810 392747, Fax +30 2810 392802, E-Mail georgoul@med.uoc.gr


 goto top of page Article Information

Received: February 27, 2004
Accepted after revision: June 24, 2004
Published online: November 24, 2005
Number of Print Pages : 7
Number of Figures : 1, Number of Tables : 3, Number of References : 35

 
Journal Home
Journal Content
Guidelines
Editorial Board
Aims and Scope
Subscriptions
Medline Abstract (ID 16319509)
Download Citation
Cited In

This journal is part of the fourth subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

Case Reports in Oncology


For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.





copyright  © 2010 S. Karger AG, Basel